Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Rating of “Moderate Buy” from Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given an average rating of “Moderate Buy” by the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $22.8182.

A number of research firms have commented on ATEC. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Loop Capital set a $25.00 price objective on shares of Alphatec in a report on Wednesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Alphatec in a research report on Monday, January 12th. Piper Sandler reissued an “overweight” rating on shares of Alphatec in a research report on Wednesday. Finally, TD Cowen restated a “buy” rating on shares of Alphatec in a research note on Tuesday, January 27th.

Key Stories Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Company reported stronger-than-expected Q4 performance on key metrics and reiterated its 2026 outlook, which supports the narrative of durable top-line growth and improving margins. Did ATEC’s Strong Q4 Beat and Reaffirmed 2026 Outlook Just Shift Alphatec Holdings’ Investment Narrative?
• Positive Sentiment: Analysts reiterated Buy ratings and raised or maintained price targets (Needham $25, H.C. Wainwright $24), which can provide upside support if guidance execution continues. Alphatec: Strengthening Earnings Leverage and Market Share Underscore Attractive Buy-Rated Risk/Reward Alphatec: Buy Rating Reaffirmed on Consistent Outperformance, Differentiated Technology, and Supportive Valuation
• Positive Sentiment: Management outlined a ~17% revenue growth target for 2026 while emphasizing improved profitability and cash flow — a forward-growth signal that investors tend to reward if delivery follows. Alphatec outlines 17-percent revenue growth target for 2026 while strengthening profitability
• Neutral Sentiment: Market write-ups and earnings-call highlights emphasize strong revenue growth and improved leverage, useful context for longer-term valuation but likely already partially priced in. Alphatec Holdings Inc (ATEC) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Post-earnings valuation pieces analyze upside vs. execution risk — helpful for investors sizing positions but not an immediate catalyst by itself. A Look At Alphatec Holdings (ATEC) Valuation After Better Than Expected Earnings And 2026 Outlook Reaffirmation
• Neutral Sentiment: Short-interest reports for late February show anomalous zero/NaN values and an effectively 0.0 days-to-cover figure — this appears to be a data/reporting issue and is unlikely to be a meaningful driver unless corrected. (internal short-interest entries)
• Negative Sentiment: An earnings-call transcript published by a third party shows a GAAP/adjusted EPS discrepancy (a reported miss on EPS vs. some market summaries showing an adjusted beat), which can create investor confusion and pressure near term until reconciliations are clarified. Alphatec Holdings, Inc. Q4 2025 Earnings Call Transcript

Alphatec Trading Down 0.2%

Shares of Alphatec stock opened at $14.01 on Friday. The stock has a 50 day moving average of $16.86 and a 200 day moving average of $17.10. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.24 and a current ratio of 2.06. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -14.75 and a beta of 1.01. Alphatec has a fifty-two week low of $8.81 and a fifty-two week high of $23.29.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Tuesday, February 24th. The medical technology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $212.93 million during the quarter, compared to analysts’ expectations of $212.67 million. Alphatec’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.23) EPS. As a group, research analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Insider Activity

In other news, Director David R. Pelizzon sold 250,000 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $19.66, for a total transaction of $4,915,000.00. Following the sale, the director owned 10,395,045 shares of the company’s stock, valued at approximately $204,366,584.70. This represents a 2.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Jennifer N. Pritzker sold 221,166 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $21.20, for a total transaction of $4,688,719.20. Following the completion of the transaction, the insider directly owned 10,673,879 shares of the company’s stock, valued at approximately $226,286,234.80. The trade was a 2.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,436,125 shares of company stock worth $29,385,878 in the last quarter. Insiders own 20.90% of the company’s stock.

Institutional Investors Weigh In On Alphatec

A number of hedge funds have recently added to or reduced their stakes in ATEC. Millennium Management LLC boosted its position in Alphatec by 292.2% in the 4th quarter. Millennium Management LLC now owns 2,225,927 shares of the medical technology company’s stock valued at $46,834,000 after buying an additional 1,658,349 shares during the period. Granite Investment Partners LLC raised its stake in shares of Alphatec by 320.6% in the second quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock valued at $19,102,000 after acquiring an additional 1,311,748 shares in the last quarter. Iron Triangle Partners LP purchased a new position in Alphatec in the fourth quarter valued at $27,051,000. Morgan Stanley grew its stake in Alphatec by 22.0% during the 4th quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company’s stock worth $91,333,000 after purchasing an additional 784,191 shares in the last quarter. Finally, Tudor Investment Corp ET AL grew its stake in Alphatec by 608.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company’s stock worth $13,093,000 after purchasing an additional 773,367 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.